Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30224827 | 0.82 | ESR1 (0.40) | SLC22A12CYP11B2GRM4CNR1PDGFRA | |
| SCHEMBL25005491 | 0.82 | ESR1 (0.40) | SLC22A12CYP11B2GRM4CNR1PDGFRA | |
| SCHEMBL22122347 | 0.80 | PDGFRA (0.35) | PDGFRACDK5TYRO3 | |
| SCHEMBL22156319 | 0.80 | SLC22A12 (0.37) | SLC22A12PDGFRACDK5TYRO3 | |
| SCHEMBL22151989 | 0.78 | PDGFRA (0.34) | CYP11B2CNR1PDGFRACDK5TYRO3 | |
| SCHEMBL22152000 | 0.78 | PDGFRA (0.34) | CYP11B2PDGFRACDK5TYRO3 | |
| SCHEMBL22151999 | 0.77 | AR (0.35) | SLC22A12CNR1PDGFRACDK5TYRO3 | |
| SCHEMBL22156543 | 0.76 | PDGFRA (0.33) | PDGFRACDK5TYRO3 | |
| SCHEMBL22128428 | 0.75 | PDGFRA (0.32) | PDGFRACDK5TYRO3 | |
| SCHEMBL22122332 | 0.74 | PDGFRA (0.32) | PDGFRACDK5TYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020132597-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | SLC22A12 4336/4885CYP11B2 3623/4885GRM4 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.